KR20030091952A - 선택적인 암 치료용의 특이적 인간 항체 - Google Patents

선택적인 암 치료용의 특이적 인간 항체 Download PDF

Info

Publication number
KR20030091952A
KR20030091952A KR10-2003-7008885A KR20037008885A KR20030091952A KR 20030091952 A KR20030091952 A KR 20030091952A KR 20037008885 A KR20037008885 A KR 20037008885A KR 20030091952 A KR20030091952 A KR 20030091952A
Authority
KR
South Korea
Prior art keywords
polypeptide
peptide
seq
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7008885A
Other languages
English (en)
Korean (ko)
Inventor
하가이요체베드
라자로비츠자넷
거이라첼
립쉬츠올리
스잔톤이스터
레바논아비그도
플락신대니얼
페레츠투비아
Original Assignee
사비언트 파마슈티컬즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사비언트 파마슈티컬즈 인코퍼레이티드 filed Critical 사비언트 파마슈티컬즈 인코퍼레이티드
Publication of KR20030091952A publication Critical patent/KR20030091952A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR10-2003-7008885A 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체 Ceased KR20030091952A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
KR20030091952A true KR20030091952A (ko) 2003-12-03

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7008885A Ceased KR20030091952A (ko) 2000-12-29 2001-12-31 선택적인 암 치료용의 특이적 인간 항체

Country Status (15)

Country Link
EP (1) EP1353937A4 (https=)
JP (1) JP2004524023A (https=)
KR (1) KR20030091952A (https=)
CN (1) CN100374456C (https=)
AU (1) AU2002246737B2 (https=)
BR (1) BR0116763A (https=)
CA (1) CA2433227A1 (https=)
CZ (1) CZ20031983A3 (https=)
HU (1) HUP0400775A2 (https=)
IL (1) IL156690A0 (https=)
MX (1) MXPA03005944A (https=)
NZ (1) NZ527173A (https=)
PL (1) PL365758A1 (https=)
RU (1) RU2316564C2 (https=)
WO (1) WO2002059264A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005101622A (ru) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) Композиции и способы терапевтического лечения
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2747154C (en) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
WO2016100533A2 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
FI3377103T4 (fi) * 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
WO1998031394A2 (en) * 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
EP1353937A2 (en) 2003-10-22
IL156690A0 (en) 2004-01-04
WO2002059264A3 (en) 2003-03-06
EP1353937A4 (en) 2005-04-13
CN1551886A (zh) 2004-12-01
HUP0400775A2 (en) 2007-05-02
PL365758A1 (en) 2005-01-10
MXPA03005944A (es) 2005-04-29
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
BR0116763A (pt) 2004-03-09
NZ527173A (en) 2006-03-31
CA2433227A1 (en) 2002-08-01
RU2003123100A (ru) 2005-03-10
CZ20031983A3 (cs) 2005-07-13
JP2004524023A (ja) 2004-08-12
RU2316564C2 (ru) 2008-02-10
WO2002059264A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
US20090220486A1 (en) Antibodies and uses thereof
WO2001075110A2 (en) Mucin-1 specific binding members and methods of use thereof
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
US7132510B2 (en) Specific human antibodies for selective cancer therapy
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
MXPA03005945A (es) Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos.
JP2005503756A5 (https=)
US20040202665A1 (en) Compositions and methods for therapeutic treatment
CA2491363A1 (en) Antibodies and uses thereof
JP2007528711A (ja) 抗体及びその使用
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
US20040208877A1 (en) Antibodies and uses thereof
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I